Skip to main content
PMC home page
Frontiers in Microbiology logoLink to Frontiers in Microbiology
. 2012 Jun 1;3:190. doi: 10.3389/fmicb.2012.00190

Antibody Peptide Based Antifungal Immunotherapy

Walter Magliani 1,*, Stefania Conti 1, Laura Giovati 1, Pier Paolo Zanello 1, Martina Sperindè 1, Tecla Ciociola 1, Luciano Polonelli 1
PMCID: PMC3365853  PMID: 22675322

Abstract

Fungal infections still represent relevant human illnesses worldwide and some are accompanied by unacceptably high mortality rates. The limited current availability of effective and safe antifungal agents makes the development of new drugs and approaches of antifungal vaccination/immunotherapy every day more needed. Among them, small antibody(Ab)-derived peptides are arousing great expectations as new potential antifungal agents. In this topic, the search path from the study of the yeast killer phenomenon to the production of Ab-derived peptides characterized by in vitro and in vivo fungicidal activity will be focused. In particular, Abs that mimic the antimicrobial activity of a killer toxin (“antibiobodies”) and antifungal peptides derived from antibiobodies (killer peptide) and other unrelated Abs [complementarity determining regions (CDR)-based and constant region (Fc)-based synthetic peptides] are described. Mycological implications in terms of reevaluation of the yeast killer phenomenon, roles of antibiobodies in antifungal immunity, of β-glucans as antifungal targets and vaccines, and of Abs as sources of an unlimited number of sequences potentially active as new immunotherapeutic tools against fungal agents and related mycoses, are discussed.

Keywords: antifungal antibodies, killer toxin, antibiobodies, synthetic CDRs, killer peptides, antifungal peptides

Introduction

Fungal infections still represent relevant human illnesses worldwide and often are sentinel markers of immunological primary disorders or induced suppression (Vinh, 2011). Some mucocutaneous infections can be persistent or refractory and involve much of the population, such as vulvovaginal candidiasis that may affect up to 75% of women at least once in their childbearing age (Sobel, 1997). More problematic are invasive fungal infections (IFIs) that are dramatically increasing and are often severe, difficult to treat, and accompanied by unacceptably high mortality rates. Aspergillosis, cryptococcosis, and invasive candidiasis are among the most widespread, less treatable, and life-threatening IFIs. They are emerging with increasing frequency, typically in the setting of immunocompromised patients, even those treated with new antifungal drugs (Wisplinghoff et al., 2004; Kauffman, 2006; Binder and Lass-Flörl, 2011). This poses a serious threat to public health, taking into account that the currently available antifungal agents are limited in number, and often their prolonged administration can have significant toxicity. Even newer antifungal agents have important limitations related to their spectrum of activity, pharmacokinetics, and drug–drug interactions. The increasing resistance to old and new antifungals makes the situation even more complicated and far from satisfactory. On the one hand, therefore, the development of new antifungal drugs is becoming every day more demanding (Zhai and Lin, 2011), the other, much attention has been paid in recent years to new approaches of antifungal vaccination and/or immunotherapy. In this Research Topic, the search path from the study of the yeast killer phenomenon to the production of antibodies (Abs) that mimic the antimicrobial activity of a killer toxin (KT) to Ab-derived peptides characterized by fungicidal activity will be focused.

From Killer Toxin to “Antibiobodies”

The demonstration that the killer effect, which was previously considered to be restricted to conspecific yeasts, was extensible to taxonomically unrelated fungi opened unannounced perspectives in antifungal therapy (Polonelli and Morace, 1986). KTs are exotoxins, generally proteins or glycoproteins, that exert their antifungal activity with different mechanisms of action by means of a preliminary, basic interaction with specific cell-wall receptors (KTRs; Magliani et al., 1997b). The therapeutic effect of a wide-spectrum KT, produced by Wickerhamomyces anomalus (formerly Pichia anomala and Hansenula anomala; PaKT), in the topical treatment of experimentally induced pityriasis versicolor-like lesions suggested the possible use of KTs as potential new antifungals (Polonelli et al., 1986). This was later ruled out because of the characteristics of PaKT in terms of toxicity, as well as antigenicity and instability in the physiological milieu (Pettoello-Mantovani et al., 1995). The production and characterization of a monoclonal Ab (mAb KT4), capable of neutralizing the fungicidal activity of PaKT (Polonelli and Morace, 1987), allowed its use as an immunogen in rabbit for the production of anti-idiotypic (anti-Id) Abs that competed with PaKT for the binding site of mAb KT4 and, most importantly, were able to kill in vitro cells of Candida albicans, adopted as fungus model, thereby mimicking the effect of PaKT (Polonelli and Morace, 1988). PaKT-like anti-Id Abs allowed to visualize, by immunofluorescence, PaKTRs on C. albicans cell wall, but not on mammalian cells (Polonelli et al., 1990). The preferential location of PaKTRs in budding scars and germ tubes, where inner cell-wall components are synthesized and exposed on the surface before being buried beneath the dense mannoprotein outermost coat, confirmed other observations on the greater susceptibility to PaKT of cells in their active phase of growth and then suggested a role of inner components, such as β-glucans (BGs), as PaKTR constituents (Guyard et al., 2002). Affinity chromatography purified anti-Id Abs were likewise able to visualize PaKTRs also in PaKT-producing cells and to kill them, which are normally resistant to the activity of their own KT. The killer activity of anti-Id Abs could be neutralized by pre-incubation with mAb KT4, thus supporting the specificity of their action. PaKT-like Abs able to exert a direct fungicidal activity, without the intervention of other factors or cells of the immune system, were defined “antibiobodies” (antibiotic-like Abs; Polonelli et al., 1991).

Antibiobodies showed to compete with PaKT for both the combinatorial site of the neutralizing mAb KT4 and PaKTRs of susceptible microorganisms suggesting, therefore, their three-dimensional structural and functional homology. As antibiobodies could be considered to mimic in some way the fungicidal activity of PaKT, the combinatorial site of mAb KT4 could be considered as a mimic of PaKTR. Based on these considerations, studies on “idiotypic vaccination,” using mAb KT4 as parenteral or mucosal immunogen to stimulate the production of antibiobodies in different formats and experimental conditions, were carried out. Polyclonal antibiobodies elicited in mice or rats immunized with mAb KT4 induced protection against experimental systemic or vaginal infections, respectively, caused by PaKT-susceptible C. albicans cells. The protection was associated with rising titers of circulating or mucosal antibiobodies. MAb KT4 affinity chromatography purified antibiobodies were capable of killing C. albicans cells in vitro and were able to passively transfer the protective state to non-immunized animals (Polonelli et al., 1993, 1994). PaKT-like antibiobodies were also produced in unlimited quantities of indefinitely available formats. Thus, monoclonal (mAb K10) and recombinant single-chain (scFv H6) antibiobodies were produced by immunization of rats and mice, respectively, with mAb KT4 using established hybridoma and recombinant DNA technologies. Both antibiobodies formats proved to be candidacidal in vitro and to compete with PaKT for the specific PaKTR on C. albicans cells. The fungicidal activity of mAb K10 and scFv H6 was neutralized by mAb KT4 and, when administered at the time of challenge or postchallenge in an experimental model of vaginal candidiasis, they proved to exert a significant therapeutic activity (Magliani et al., 1997a; Polonelli et al., 1997).

As an obvious corollary, natural antireceptor antibiobodies were detected in the serum or secretions of animals and humans undergoing experimental or natural infections caused by PaKT-susceptible C. albicans cells. Rising titers of fungicidal Abs could be detected, after intravaginal or intragastric inoculations of PaKTR-bearing C. albicans cells, in vaginal fluids of rats previously vaccinated or never immunized with mAb KT4. Antireceptor antibiobodies were also consistently found in the vaginal fluid of women afflicted with recurrent vaginal candidiasis, as well as in the serum, saliva, and/or bronchial washing of HIV positive patients with oral or lung infections caused by PaKTR-bearing fungi. Similar to what previously observed, affinity chromatography purified human natural antibiobodies were capable of killing C. albicans cells in vitro and their activity was neutralized by mAb KT4. These antibiobodies were also able to passively transfer the protective state to non-immunized animals (Polonelli et al., 1996).

The natural existence of candidacidal Abs as part of the Ab response against C. albicans added significance to the growing evidence on the importance of Ab-mediated acquired immunity for host defense against candidiasis and other relevant fungal infections (Casadevall et al., 1998). The availability, moreover, of reproducible antibiobodies in different formats and unlimited amounts, potentially free of undesired toxic effects, suggested the feasibility of new therapeutic approaches for the immunotherapy of candidiasis (Magliani et al., 2002). Based on the wide antifungal spectrum of PaKT and the potential diffusion of PaKTRs (Magliani et al., 1997b), antibiobodies should display a fungicidal activity against various fungal agents. While PaKT’s activity was severely limited by the environmental conditions, being manifested at acidic pH (4.6) and temperatures around 28°C, antibiobodies proved to be active in physiological conditions (pH 7 and 37°C). Conversely, the idiotype of mAb KT4 or purified PaKTR could be suggested as potential antifungal vaccines.

Human natural antibiobodies proved to exert in vitro a strong and specific inhibitory activity against rat-derived P. carinii organisms, in terms of attachment to cultured cells and infectivity to nude rats. This activity could be abolished by their previous incubation with mAb KT4. Immunofluorescence studies of competition with PaKT showed that antibiobodies efficiently bound to specific PaKTRs on the surface of P. carinii cells (Séguy et al., 1997). Pneumocystosis (PCP) extension was significantly reduced by aerosol administration of mAb K10 in a PCP experimental nude rat model (Séguy et al., 1998). In a murine model of allogeneic T-cell-depleted bone marrow transplantation, treatment with mAb K10 protected mice with profound neutropenia from experimental invasive pulmonary aspergillosis in terms of long-term survival and decreased pathology associated with inhibition of fungal growth and chitin content in the lungs. This finding was supported by the in vitro effect of mAb K10 against Aspergillus fumigatus swollen conidia (inhibition of the hyphal development and metabolic activity; Cenci et al., 2002). A Gram-positive generally recognized as safe bacterium, Streptococcus gordonii, was engineered to produce scFv H6 as molecules secreted or displayed on the bacterial surface. Recombinant bacteria were able to stably colonize vaginal mucosa, and proved to be as efficacious as fluconazole in rapidly abating the fungal burden and in curing the infection in a rat model of experimental candidiasis (Beninati et al., 2000).

From Antibiobodies to Killer Peptide

Synthetic peptides derived from the sequence of scFv H6 could still display in vitro candidacidal activity. In particular, a decapeptide containing the first three amino acids of the light chain (L) complementarity determining region (CDR)1, with an alanine replacement of its first residue (AKVTMTCSAS), proved to exert a strong candidacidal activity in vitro, and was therefore designated killer peptide (KP). Significantly, KP competed with mAb K10 for binding to germinating cells of C. albicans. Furthermore, KP demonstrated a significant therapeutic activity against infections caused by fluconazole-susceptible or -resistant C. albicans strains in a rat model of vaginal candidiasis as well as against systemic candidal infections in immunocompetent or severely immunocompromised mice (Polonelli et al., 2003). Thus, KP proved to act as functional mimotope of PaKT. KP demonstrated a broad antifungal spectrum without any detectable toxicity (Magliani et al., 2004a). Rapid candidacidal activity of KP was confirmed in time-killing studies and proved to be inhibited, in a dose-dependent fashion, by laminarin, a soluble 1,3-BG (Magliani et al., 2004b). KP was able to kill, in vitro, both capsular and acapsular Cryptococcus neoformans cells and impaired the production of specific virulence factors, such as the capsule, rendering the fungus more susceptible to natural effector cells. More importantly, KP reduced significantly the fungal burden in immunosuppressed mice with cryptococcosis and protected most of them from an otherwise lethal experimental infection (Cenci et al., 2004). KP demonstrated a significant activity against Paracoccidioides brasiliensis and experimental paracoccidioidomycosis being fungicidal in vitro, even in its d-isomeric form, and therapeutic in vivo by markedly reducing the fungal load in target organs (liver, lung, spleen) of infected animals (Travassos et al., 2004).

Killer peptide exerted a strong dose-dependent candidacidal activity against a large number of candidal strains isolated from saliva of adult diabetic and non-diabetic subjects, regardless of their species and pattern of resistance to conventional antifungal drugs (Manfredi et al., 2005). KP showed killing activity on C. albicans cells even adhered to sanded acrylic resin disks, a major condition in which candidal biofilms are formed (Manfredi et al., 2007).

The spectrum of KP activity was subsequently extended to phytopathogenic fungal agents, such as Botrytis cinerea and Fusarium oxysporum. KP was expressed in an active form in plants (Nicotiana benthamiana) by using a Potato virus X-derived vector. KP-expressing plants showed enhanced resistance to an experimental bacterial challenge with Pseudomonas. syringae pv. tabaci (Donini et al., 2005).

Killer peptide, moreover, was able to bind selectively to murine dendritic cells (DCs) and, to a lesser extent, to macrophages, possibly through major histocompatibility complex (MHC) class II, CD16/32, and cellular molecules recognized by anti-specific intercellular adhesion molecule-grabbing non-integrin R1 Abs. The peptide proved to modulate the multiple functions of DCs, improving their capacity to induce better immune antimicrobial response (Cenci et al., 2006).

The fungicidal activity of KP was apparently based on a new mechanism of action as no resistant mutant was found by testing a wide Saccharomyces cerevisiae non-essential gene deletion strain library that included isolates resistant to conventional antifungal drugs such as caspofungin and fluconazole (Conti et al., 2008).

Even though the precise molecular mechanism of action has still to be clarified, KP caused in C. albicans the appearance of significant internal alterations, such as cell-wall swelling, plasma membrane collapse, and condensation and fragmentation of nuclear material, similar to those observed by treatment of the yeast cells with classical apoptotic agents (Magliani et al., 2008b). KP proved to be very stable in its lyophilized form and, when solubilized in non-reducing conditions, due to the presence of a cysteine residue, it could easily dimerize by formation of disulfide bridges. KP dimer turned out to be the functional unit as confirmed by the instant and total candidacidal effect showed by the dimeric molecule synthesized ad hoc. After dimerization, KP revealed its ability to spontaneously and reversibly self-assemble in an organized network of fibril-like structures that resembled physical hydrogels. This process was catalyzed by the addition of 1,3-BG, as soluble laminarin or C. albicans cells exposing BGs on their surface, that caused an immediate conformational conversion of the peptide from random coil to antiparallel β-sheet. This self-assembled state was concentration- and temperature-dependent and could provide protection against proteases and assure a release of the active form over time. KP was proposed as paradigmatic of a new class of autodelivering therapeutic peptides (Pertinhez et al., 2009).

From Killer Peptide to Ab-Derived Antifungal Peptides

All the peptides reproducing the six CDRs of scFv H6 showed candidacidal activity in vitro, even if to a lesser extent compared to KP (Polonelli et al., 2003). Other Abs have been reported meanwhile as characterized by direct antifungal activity: a human anti-heat shock protein 90 recombinant Ab (Mycograb; Matthews et al., 2003); a mAb (C7), directed to a protein epitope of a C. albicans cell-wall stress mannoprotein, that, besides its candidacidal activity, proved to exert inhibition of both adhesion and filamentation as well as blockage of the reductive iron uptake pathway of the yeast (Moragues et al., 2003; Brena et al., 2011); a scFv and a scFv-derived peptide able to mimic the fungicidal activity of the H. anomala HM-1 KT (Selvakumar et al., 2006; Kabir et al., 2011). The existence of a family of antifungal Abs, from which new innovative wide-spectrum fungicidal tools could be properly derived, was suggested (Magliani et al., 2005).

As seen in available databases, the sequence of P6, the peptide from which KP was derived, was present within the V regions of many unrelated Abs. On this basis, it was speculated that CDR-related peptides may display antifungal activity regardless of their specificities. Synthetic peptides with sequences identical to the CDRs of mAb C7 were proved for candidacidal activity in comparison to the CDRs of two unrelated Abs, whose variable region sequences were deposited and available. A murine IgM (mAb pc42), directed to a synthetic peptide containing the surface antigen of hepatitis B virus and the T-helper-cell epitope from the circumsporozoite protein of Plasmodium falciparum, was selected because it shared CDR H1 and H2 with mAb C7. A human IgM (mAb HuA), specific for difucosyl human blood group A substance, was selected because not sharing any sequence homology with either mAb C7 or mAb pc42 CDRs and because representing an Ab widely diffused in normal population. When tested in in vitro and in vivo experimental models against C. albicans, some CDR peptides showed differential fungicidal and therapeutic activities. Alanine substituted derivatives of candidacidal CDR peptides showed further differential increased, unaltered, or decreased candidacidal activity. Thus, short synthetic CDR-related peptides may display fungicidal activity irrespective of Ab specificity for a given antigen, conceivably involving different mechanisms of action. Alanine substitution can be used to increase variability of CDR peptides’ fungicidal activity (Polonelli et al., 2008). A synthetic peptide representative of CDR H3 of a murine mAb (MoA) conspecific with HuA and representing the different ways by which the same epitope can be recognized by different immune systems though presenting unrelated primary sequences, showed no candidacidal activity in vitro. MoA H3, however, was able to induce a significant increased production of proinflammatory cytokines, IL-6, and TNF-α, in murine splenocytes and peritoneal macrophages (PMs), but not in peritoneal neutrophils. Further characterization of MoA H3 allowed to visualize its binding and uptaking by PMs. This activated the Akt pathway in correlation to an increased production of TNF-α, and significantly up-regulated TLR-4 gene and protein expression. The state of PM activation could explain the therapeutic effect observed by treatment with MoA H3 in the mouse experimental model of systemic candidiasis in terms of survival and impressive decrease of candidal recovery from kidneys (Gabrielli et al., 2009).

Mycological Implications

These studies contributed to the advancement of knowledge on various aspects of treatment and control of fungal diseases. In particular, they suggested unusual considerations and perspectives on potential therapeutic and prophylactic approaches based on the yeast killer phenomenon, idiotypic vaccination, antibiobodies, and Ab-derived peptides.

Reevaluation of the yeast killer phenomenon

Given the impossibility of directly using KTs as antifungal therapeutic agents, their fungicidal properties have been harnessed by generating Ab derivatives. The production of antibiobodies and Ab-derived antimicrobial peptides (Magliani et al., 1997b, 2008b; Selvakumar et al., 2006; Kabir et al., 2011) suggests that very similar approaches can be applied with other KTs. Different antifungal molecules could be obtained, thereby taking advantage of the mimic of a widely spread natural phenomenon. Unraveling their mechanisms of action could result in the discovery of new potential targets for antifungal agents and/or immunoprevention, such as 1,3-BG, the suggested target of antibiobodies and Ab-derived antimicrobial peptides.

Antibiobodies and humoral antifungal immunity

The relative importance of cell-mediated (CMI) and humoral immunity against fungal infections has been longly debated. While CMI continues to be rightly considered the primary mechanism for antifungal defense, Ab response has been increasingly taken into consideration (Polonelli et al., 2000). In particular, antibiobodies were shown to occur in the Ab repertoire mounted during fungal infections caused by PaKT-sensitive fungi. Their clinical relevance, however, still needs to be determined. They may represent only a minor part of the plethora of Abs produced during experimental or natural infections by PaKTR-bearing fungal organisms and they could be very scarcely produced in vivo being unable to reach protective titers. The occurrence of interfering Abs of different specificities and isotype, moreover, could explain the negative results often achieved in active and passive immunoprotection experiments based on humoral immunity. The interplay between protective and interfering Abs could dictate the outcome of fungal infections and may also help to explain why subjects with elevated anti-Candida Ab titers could remain nonetheless susceptible to candidiasis (Bromuro et al., 2002). The observations made in the past decade, showing that Abs can function as direct effector molecules against fungi, suggest the need for new conceptual approaches in the understanding of humoral immunity to fungal infections (Casadevall and Pirofski, 2011).

β-glucans as critical viability molecules, antifungal targets, and vaccines

BGs, 1,3-BG in particular, have emerged as viability-critical inner components of many fungal cell walls and were reasonably suggested as PaKTRs constituents. While 1,3-BGs are biosynthesized by a wide range of fungal species, they are not produced by mammalian cells (Magliani et al., 2008a). In the fungal cell wall, 1,3-BGs are usually masked beneath the dense mannoprotein outermost layer and this may protect them by recognition of Abs. When exposed on the surface, mainly during the active phase of growth, such as in budding cells and germ tubes in C. albicans (Iorio et al., 2008), BGs can represent a relevant fungal virulence factor being recognized as major pathogen associated molecular pattern able to act as potent proinflammatory molecules. Their critical structural role was underscored by the discovery of a new class of antifungals, the echinocandins, that are fungicidal by inhibiting the 1,3-BG synthesis (Denning, 2003) and by reports on antibiobodies and Ab-derived peptides. An innovative antifungal vaccine composed of laminarin, a soluble poorly immunogenic linear polymer of 1,3-BG purified from the brown alga Laminaria digitata, conjugated with diphtheria toxoid CRM197, was developed. In animal models, the elicited Abs proved to protect against ascomycetous and basidiomycetous fungal agents, such as A. fumigatus, C. albicans, and C. neoformans (Torosantucci et al., 2005; Rachini et al., 2007; Bromuro et al., 2010). As outlined by Casadevall and Pirofski, these observations introduced a fungal heresy into the immunological dogma that effective immune responses should be pathogen specific and that Abs to “common,” “universal,” or “cross-reactive” antigens may not be protective. In the case of 1,3-BG, over all derived from a non-fungal source, a single vaccine induced protection against three major fungal pathogens. Furthermore, this provides a vulnerable Achilles heel for Ab-mediated antifungal protection, suggesting the possibility to develop Abs for passive therapy of the diseases caused by each of these fungal pathogens (Casadevall and Pirofski, 2007). Recently, radiolabeled Abs to BG and other common fungal antigens as well as plant-derived recombinant Abs to BG have been described and proposed as universal tools for fungal disease (Capodicasa et al., 2011; Bryan et al., 2012). 1,3-BG-conjugated vaccines can be seen as “universal” vaccines that could be administered to patients who share risk factors (e.g., neutropenia) to immunize them, before they become debilitated and immunocompromised, against all of the main opportunistic fungal agents (Cassone and Rappuoli, 2010). Further studies will hopefully clarify all the different aspects in this field, including the role that anti-BG Abs, that are ubiquitous at low levels in human sera, may play in determining susceptibility or resistance to fungal infections (Chiani et al., 2009).

Ab-derived peptides as new immunotherapeutic tools

The concept that short synthetic peptides corresponding to segments of variable region of immunoglobulins (Igs), CDRs particularly, may display antifungal activities regardless of the specificity of the belonging Ab was claimed. This opened new perspectives in the field of antifungal therapy and encouraged to continue research on Abs as source of fungicidal peptides. Peptides encompassing sequences of the constant region of mammalian Abs (Fc-peptides) belonging to different isotypes (IgG, IgM, IgA), putatively released in vivo by proteolysis of Igs, were synthesized. Selected Fc-peptides proved to exert a fungicidal activity in vitro against pathogenic yeasts, such as C. albicans, C. glabrata, C. neoformans, and Malassezia furfur, including caspofungin and triazole resistant strains, without any hemolytic, cytotoxic, and genotoxic effect. An Fc-peptide (N10K), included in all human IgGs and selected as a proof-of-concept, displayed a therapeutic activity when administered in consolidated mouse models of systemic and vaginal candidiasis. N10K proved to spontaneously aggregate in a rich β-sheet structure and this possibly contributed to its in vivo therapeutic activity. The decapeptide bound to the surface of Candida cells, without causing major lysis. However, gross alterations in the morphology of yeast cells, with disruption of internal organelles, were seen (Polonelli et al., 2012). N10K, moreover, was able to induce in human monocytes, in vitro, IL-6 secretion, pIkB-α activation and up-regulation of Dectin-1 expression, leading to an increased activation of BG-induced pSyk, CARD9, and pIkB-α, and an increase in the production of proinflammatory cytokines, such as IL-6, IL-12, IL-1β, and TNF-α (manuscript submitted for publication). These findings may be of great interest from an immunological point of view. While significant amounts of specific fragments from the Ab variable regions, such as CDRs, are unlikely to be released in vivo, Fc-peptides could potentially occur in vivo and influence the antifungal immune response in a way reminiscent of molecules of innate immunity. Ongoing studies using mass spectrometry-based approaches are aimed to search for the presence of Fc-peptides in human sera from individuals in various clinical conditions. Positive results would shed new light on the role that Ab fragments could exert in the antifungal homeostasis. Furthermore, the reported high frequency of Ab-derived fungicidal peptides suggests that Abs, irrespective of their isotype and specificity for a given antigen, may be the source of potentially active and therapeutically exploitable molecules for devising new immunotherapeutic tools against pathogenic fungi (Magliani et al., 2009).

Conclusion

From the study of the interesting, but apparently therapeutically impracticable, yeast killer phenomenon, fungicidal antibiobodies, antibiobody-derived peptides, and Ab-derived CDR – as well as Fc-peptides were produced. Like many other proteins, such as bactericidal proteins (D’Alessio, 2011), hemoglobin (Catiau et al., 2011), Helicobacter pylori ribosomal protein L1 (Park and Hahm, 2012), human lactoferrin (Brouwer et al., 2011), human milk lysozyme (Ibrahim et al., 2011), human salivary protein (Gorr et al., 2011), and thrombin (Kasetty et al., 2011), longicin (Galay et al., 2012), thymic stromal lymphopoietin and kininogen (Sonesson et al., 2011a,b), ubiquitin (Pasikowski et al., 2011), among the most recently reported, Abs should be considered as containing many hidden peptides, known as “cryptides” (Ng and Ilag, 2006; Pimenta and Lebrun, 2007; Ueki et al., 2007; Samir and Link, 2011) in both their variable and constant regions. They can exert biological effects that cannot be predicted based on the activity of the precursor protein (Polonelli et al., 2012). These observations call into question the traditional distinction between acquired and innate immunity, suggesting a further close link between them. Ab-derived antifungal peptides, on the other hand, may be promising molecules for future therapeutic developments. Their easy production, engineering, and chemical optimization, through aminoacidic substitutions, peptidomimetics, etc., can greatly expand the possibilities of obtaining effective antifungal immunotherapeutic tools. These approaches may reasonably fall within the “fragment-based drug discovery,” i.e., the design of good-quality lead compounds from fragment hits that can be developed into clinical candidates (Foloppe, 2011).

Future studies on Ab-derived peptides will be addressed to better clarify their molecular mechanisms of fungicidal action, presumably leading to the discovery of cellular targets for new therapeutic antifungal approaches in the never ending war against fungal diseases.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgments

Part of the work described in the manuscript has been supported by funding from the Italian Ministry of Health in the frame of the National AIDS Research Program (last grant number 40H39). The funder had no role in decision to publish or preparation of the manuscript.

References

  1. Beninati C., Oggioni M. R., Boccanera M., Spinosa M. R., Maggi T., Conti S., Magliani W., De Bernardis F., Teti G., Cassone A., Pozzi G., Polonelli L. (2000). Therapy of mucosal candidiasis by expression of an anti-idiotype in human commensal bacteria. Nat. Biotechnol. 18, 1060–1064 10.1038/80250 [DOI] [PubMed] [Google Scholar]
  2. Binder U., Lass-Flörl C. (2011). Epidemiology of invasive fungal infections in the Mediterranean area. Mediterr. J. Hematol. Infect. Dis. 3, e20110016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Brena S., Cabezas-Olcoz J., Moragues M. D., Fernández de Larrinoa I., Domínguez A., Quindós G., Pontón J. (2011). Fungicidal monoclonal antibody C7 interferes with iron acquisition in Candida albicans. Antimicrob. Agents Chemother. 55, 3156–3163 10.1128/AAC.00892-10 [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bromuro C., Romano M., Chiani P., Berti F., Tontini M., Proietti D., Mori E., Torosantucci A., Costantino P., Rappuoli R., Cassone A. (2010). Beta-glucan-CRM197 conjugates as candidates antifungal vaccines. Vaccine 28, 2615–2623 10.1016/j.vaccine.2010.01.012 [DOI] [PubMed] [Google Scholar]
  5. Bromuro C., Torosantucci A., Chiani P., Conti S., Polonelli L., Cassone A. (2002). Interplay between protective and inhibitory antibodies dictates the outcome of experimentally disseminated candidiasis in recipients of a Candida albicans vaccine. Infect. Immun. 70, 5462–5470 10.1128/IAI.70.10.5462-5470.2002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Brouwer C. P., Rahman M., Welling M. M. (2011). Discovery and development of a synthetic peptide derived from lactoferrin for clinical use. Peptides 32, 1953–1963 10.1016/j.peptides.2011.07.017 [DOI] [PubMed] [Google Scholar]
  7. Bryan R. A., Guimaraes A. J., Hopcraft S., Jiang Z., Bonilla K., Morgenstern A., Bruchertseifer F., Del Poeta M., Torosantucci A., Cassone A., Nosanchuk J. D., Casadevall A., Dadachova E. (2012). Toward developing a universal treatment for fungal disease using radioimmunotherapy targeting common fungal antigens. Mycopathologia. 173, 463–471 10.1007/s11046-011-9476-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Capodicasa C., Chiani P., Bromuro C., De Bernardis F., Catellani M., Palma A. S., Liu Y., Feizi T., Cassone A., Benvenuto E., Torosantucci A. (2011). Plant production of anti-β-glucan antibodies for immunotherapy of fungal infections in humans. Plant Biotechnol. J. 9, 776–787 10.1111/j.1467-7652.2010.00586.x [DOI] [PubMed] [Google Scholar]
  9. Casadevall A., Cassone A., Bistoni F., Cutler J. E., Magliani W., Murphy J. W., Polonelli L., Romani L. (1998). Antibody and/or cell-mediated immunity, protective mechanisms in fungal disease: an ongoing dilemma or an unnecessary dispute? Med. Mycol. 36(Suppl. 1), 95–105 [PubMed] [Google Scholar]
  10. Casadevall A., Pirofski L. A. (2007). Antibody-mediated protection through cross-reactivity introduces a fungal heresy into immunological dogma. Infect. Immun. 75, 5074–5078 10.1128/IAI.01001-07 [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Casadevall A., Pirofski L. A. (2011). A new synthesis for antibody-mediated immunity. Nat. Immunol. 13, 21–28 10.1038/ni.2184 [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Cassone A., Rappuoli R. (2010). Universal vaccines: shifting to one for many. MBio 1, e00042–e00110 10.1128/mBio.00042-10 [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Catiau L., Traisnel J., Chihib N. E., Le Flem G., Blanpain A., Melnyk O., Guillochon D., Nedjar-Arroume N. (2011). RYH: a minimal peptidic sequence obtained from beta-chain hemoglobin exhibiting an antimicrobial activity. Peptides 32, 1463–1468 10.1016/j.peptides.2010.12.016 [DOI] [PubMed] [Google Scholar]
  14. Cenci E., Bistoni F., Mencacci A., Perito S., Magliani W., Conti S., Polonelli L., Vecchiarelli A. (2004). A synthetic peptide as a novel anticryptococcal agent. Cell. Microbiol. 6, 953–961 10.1111/j.1462-5822.2004.00413.x [DOI] [PubMed] [Google Scholar]
  15. Cenci E., Mencacci A., Spreca A., Montagnoli C., Bacci A., Perruccio K., Velardi A., Magliani W., Conti S., Polonelli L., Romani L. (2002). Protection of killer antiidiotypic antibodies against early invasive aspergillosis in a murine model of allogeneic T-cell-depleted bone marrow transplantation. Infect. Immun. 70, 2375–2382 10.1128/IAI.70.5.2375-2382.2002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Cenci E., Pericolini E., Mencacci A., Conti S., Magliani W., Bistoni F., Polonelli L., Vecchiarelli A. (2006). Modulation of phenotype and function of dendritic cells by a therapeutic synthetic killer peptide. J. Leukoc. Biol. 79, 40–45 10.1189/jlb.0205113 [DOI] [PubMed] [Google Scholar]
  17. Chiani P., Bromuro C., Cassone A., Torosantucci A. (2009). Anti-beta-glucan antibodies in healthy human subjects. Vaccine 27, 513–519 10.1016/j.vaccine.2008.11.030 [DOI] [PubMed] [Google Scholar]
  18. Conti S., Magliani W., Giovati L., Libri I., Maffei D. L., Salati A., Polonelli L. (2008). Screening of a Saccharomyces cerevisiae nonessential gene deletion collection for altered susceptibility to a killer peptide. New Microbiol. 31, 143–145 [PubMed] [Google Scholar]
  19. D’Alessio G. (2011). Denatured bactericidal proteins: active per se, or reservoirs of active peptides? FEBS Lett. 585, 2403–2404 10.1016/j.febslet.2011.07.009 [DOI] [PubMed] [Google Scholar]
  20. Denning D. W. (2003). Echinocandin antifungal drugs. Lancet 362, 1142–1151 10.1016/S0140-6736(03)14472-8 [DOI] [PubMed] [Google Scholar]
  21. Donini M., Lico C., Baschieri S., Conti S., Magliani W., Polonelli L., Benvenuto E. (2005). Production of an engineered killer peptide in Nicotiana benthamiana by using a potato virus X expression system. Appl. Environ. Microbiol. 71, 6360–6367 10.1128/AEM.71.10.6360-6367.2005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Foloppe N. (2011). The benefits of constructing leads from fragment hits. Future Med. Chem. 3, 1111–1115 10.4155/fmc.11.46 [DOI] [PubMed] [Google Scholar]
  23. Gabrielli E., Pericolini E., Cenci E., Ortelli F., Magliani W., Ciociola T., Bistoni F., Conti S., Vecchiarelli A., Polonelli L. (2009). Antibody complementarity-determining regions (CDRs): a bridge between adaptive and innate immunity. PLoS ONE 4, e8187. 10.1371/journal.pone.0008187 [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Galay R. L., Maeda H., Aung K. M., Umemiya-Shirafuji R., Xuan X., Igarashi I., Tsuji N., Tanaka T., Fujisaki K. (2012). Anti-babesial activity of a potent peptide fragment derived from longicin of Haemaphysalis longicornis. Trop. Anim. Health Prod. 44, 343–348 10.1007/s11250-011-0027-7 [DOI] [PubMed] [Google Scholar]
  25. Gorr S. U., Abdolhosseini M., Shelar A., Sotsky J. (2011). Dual host-defence functions of SPLUNC2/PSP and synthetic peptides derived from the protein. Biochem. Soc. Trans. 39, 1028–1032 10.1042/BST0391028 [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Guyard C., Dehecq E., Tissier J. P., Polonelli L., Dei-Cas E., Cailliez J. C., Menozzi F. D. (2002). Involvement of [beta]-glucans in the wide-spectrum antimicrobial activity of Williopsis saturnus var. mrakii MUCL 41968 killer toxin. Mol. Med. 8, 686–694 [PMC free article] [PubMed] [Google Scholar]
  27. Ibrahim H. R., Imazato K., Ono H. (2011). Human lysozyme possesses novel antimicrobial peptides within its N-terminal domain that target bacterial respiration. J. Agric. Food Chem. 59, 10336–10345 [DOI] [PubMed] [Google Scholar]
  28. Iorio E., Torosantucci A., Bromuro C., Chiani P., Ferretti A., Giannini M., Cassone A., Podo F. (2008). Candida albicans cell wall comprises a branched beta-D-(1→6)-glucan with beta-D-(1→3)-side chains. Carbohydr. Res. 343, 1050–1061 10.1016/j.carres.2008.02.020 [DOI] [PubMed] [Google Scholar]
  29. Kabir M. E., Karim N., Krishnaswamy S., Selvakumar D., Miyamoto M., Furuichi Y., Komiyama T. (2011). Peptide derived from anti-idiotypic single-chain antibody is a potent antifungal agent compared to its parent fungicide HM-1 killer toxin peptide. Appl. Microbiol. Biotechnol. 92, 1151–1160 10.1007/s00253-011-3412-2 [DOI] [PubMed] [Google Scholar]
  30. Kasetty G., Papareddy P., Kalle M., Rydengård V., Mörgelin M., Albiger B., Malmsten M., Schmidtchen A. (2011). Structure-activity studies and therapeutic potential of host defense peptides of human thrombin. Antimicrob. Agents Chemother. 55, 2880–2890 10.1128/AAC.01515-10 [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Kauffman C. A. (2006). Fungal infections. Proc. Am. Thorac. Soc. 3, 35–40 10.1513/pats.200510-110JH [DOI] [PubMed] [Google Scholar]
  32. Magliani W., Conti S., Cassone A., De Bernardis F., Polonelli L. (2002). New immunotherapeutic strategies to control vaginal candidiasis. Trends Mol. Med. 8, 121–126 10.1016/S1471-4914(01)02268-7 [DOI] [PubMed] [Google Scholar]
  33. Magliani W., Conti S., Cunha R. L., Travassos L. R., Polonelli L. (2009). Antibodies as crypts of antiinfective and antitumor peptides. Curr. Med. Chem. 16, 2305–2323 10.2174/092986709788453104 [DOI] [PubMed] [Google Scholar]
  34. Magliani W., Conti S., De Bernardis F., Gerloni M., Bertolotti D., Mozzoni P., Cassone A., Polonelli L. (1997a). Therapeutic potential of antiidiotypic single chain antibodies with yeast killer toxin activity. Nat. Biotechnol. 15, 155–158 10.1038/nbt0297-155 [DOI] [PubMed] [Google Scholar]
  35. Magliani W., Conti S., Gerloni M., Bertolotti D., Polonelli L. (1997b). Yeast killer systems. Clin. Microbiol. Rev. 10, 369–400 [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Magliani W., Conti S., Frazzi R., Ravanetti L., Maffei D. L., Polonelli L. (2005). Protective antifungal yeast killer toxin-like antibodies. Curr. Mol. Med. 5, 443–452 10.2174/1566524054022558 [DOI] [PubMed] [Google Scholar]
  37. Magliani W., Conti S., Giovati L., Maffei D. L., Polonelli L. (2008a). Anti-beta-glucan-like immunoprotective candidacidal antiidiotypic antibodies. Front. Biosci. 13, 6920–6937 10.2741/3199 [DOI] [PubMed] [Google Scholar]
  38. Magliani W., Conti S., Travassos L. R., Polonelli L. (2008b). From yeast killer toxins to antibiobodies and beyond. FEMS Microbiol. Lett. 288, 1–8 10.1111/j.1574-6968.2008.01340.x [DOI] [PubMed] [Google Scholar]
  39. Magliani W., Conti S., Salati A., Arseni S., Ravanetti L., Frazzi R., Polonelli L. (2004a). Engineered killer mimotopes: new synthetic peptides for antimicrobial therapy. Curr. Med. Chem. 11, 1793–1800 [DOI] [PubMed] [Google Scholar]
  40. Magliani W., Conti S., Salati A., Vaccari S., Maffei D. L., Polonelli L. (2004b). Therapeutic potential of yeast killer toxin-like antibodies and mimotopes. FEMS Yeast Res. 5, 11–18 10.1016/j.femsyr.2004.06.010 [DOI] [PubMed] [Google Scholar]
  41. Manfredi M., McCullough M. J., Conti S., Polonelli L., Vescovi P., Al-Karaawi Z. M., Porter S. R. (2005). In vitro activity of a monoclonal killer anti-idiotypic antibody and a synthetic killer peptide against oral isolates of Candida spp. differently susceptible to conventional antifungals. Oral Microbiol. Immunol. 20, 226–232 10.1111/j.1399-302X.2005.00217.x [DOI] [PubMed] [Google Scholar]
  42. Manfredi M., Merigo E., Salati A., Conti S., Savi A., Polonelli L., Bonanini M., Vescovi P. (2007). In vitro candidacidal activity of a synthetic killer decapeptide (KP) against Candida albicans cells adhered to resin acrylic discs. J. Oral Pathol. Med. 36, 468–471 10.1111/j.1600-0714.2007.00561.x [DOI] [PubMed] [Google Scholar]
  43. Matthews R. C., Rigg G., Hodgetts S., Carter T., Chapman C., Gregory C., Illidge C., Burnie J. (2003). Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90. Antimicrob. Agents Chemother. 47, 2208–2216 10.1128/AAC.47.7.2208-2216.2003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Moragues M. D., Omaetxebarria M. J., Elguezabal N., Sevilla M. J., Conti S., Polonelli L., Ponton J. (2003). A monoclonal antibody directed against a Candida albicans cell wall mannoprotein exerts three anti-C. albicans activities. Infect. Immun. 71, 5273–5279 10.1128/IAI.71.9.5273-5279.2003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Ng J. H., Ilag L. L. (2006). Cryptic protein fragments as an emerging source of peptide drugs. IDrugs 9, 343–346 [PubMed] [Google Scholar]
  46. Park Y., Hahm K. S. (2012). Novel short AMP: design and activity study. Protein Pept. Lett. 19, 652–656 [DOI] [PubMed] [Google Scholar]
  47. Pasikowski P., Gozdziewicz T., Stefanowicz P., Artym J., Zimecki M., Szewczuk Z. (2011). A novel immunosuppressory peptide originating from the ubiquitin sequence. Peptides 32, 2418–2427 10.1016/j.peptides.2011.10.002 [DOI] [PubMed] [Google Scholar]
  48. Pertinhez T. A., Conti S., Ferrari E., Magliani W., Spisni A., Polonelli L. (2009). Reversible self-assembly: a key feature for a new class of autodelivering therapeutic peptides. Mol. Pharm. 6, 1036–1039 10.1021/mp900024z [DOI] [PubMed] [Google Scholar]
  49. Pettoello-Mantovani M., Nocerino A., Polonelli L., Morace G., Conti S., Di Martino L., De Ritis G., Iafusco M., Guandalini S. (1995). Hansenula anomala killer toxin induces secretion and severe acute injury in the rat intestine. Gastroenterology 109, 1900–1906 10.1016/0016-5085(95)90757-2 [DOI] [PubMed] [Google Scholar]
  50. Pimenta D. C., Lebrun I. (2007). Cryptides: buried secrets in proteins. Peptides 28, 2403–2410 10.1016/j.peptides.2007.10.005 [DOI] [PubMed] [Google Scholar]
  51. Polonelli L., Casadevall A., Han Y., Bernardis F., Kirkland T. N., Matthews R. C., Ariani D., Boccanera M., Burnie J. P., Cassone A., Conti S., Cutler J. E., Frazzi R., Gregory C., Hodgetts S., Illidge C., Magliani W., Rigg G., Santoni G. (2000). The efficacy of acquired humoral and cellular immunity in the prevention and therapy of experimental fungal infections. Med. Mycol. 38(Suppl. 1), 281–292 10.1080/mmy.38.1.281.292 [DOI] [PubMed] [Google Scholar]
  52. Polonelli L., Ciociola T., Magliani W., Zanello P. P., D’Adda T., Galati S., De Bernardis F., Arancia S., Gabrielli E., Pericolini E., Vecchiarelli A., Arruda D. C., Pinto M. R., Travassos L. R., Pertinhez T. A., Spisni A., Conti S. (2012). Peptides of the constant region of antibodies display fungicidal activity. PLoS ONE 7, e34105. 10.1371/journal.pone.0034105 [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Polonelli L., Conti S., Gerloni M., Magliani W., Castagnola M., Morace G., Chezzi C. (1991). “Antibiobodies”: antibiotic-like anti-idiotypic antibodies. J. Med. Vet. Mycol. 29, 235–242 10.1080/02681219180000351 [DOI] [PubMed] [Google Scholar]
  54. Polonelli L., De Bernardis F., Conti S., Boccanera M., Gerloni M., Morace G., Magliani W., Chezzi C., Cassone A. (1994). Idiotypic intravaginal vaccination to protect against candidal vaginitis by secretory, yeast killer toxin-like anti-idiotypic antibodies. J. Immunol. 152, 3175–3182 [PubMed] [Google Scholar]
  55. Polonelli L., De Bernardis F., Conti S., Boccanera M., Magliani W., Gerloni M., Cassone A. (1996). Human natural yeast killer toxin-like candidacidal antibodies. J. Immunol. 156, 1880–1885 [PubMed] [Google Scholar]
  56. Polonelli L., Fanti F., Conti S., Campani L., Gerloni M., Castagnola M., Morace G., Chezzi C. (1990). Detection by immunofluorescent anti-idiotypic antibodies of yeast killer toxin cell wall receptors of Candida albicans. J. Immunol. Methods 132, 205–209 10.1016/0022-1759(90)90031-P [DOI] [PubMed] [Google Scholar]
  57. Polonelli L., Lorenzini R., De Bernardis F., Gerloni M., Conti S., Morace G., Magliani W., Chezzi C. (1993). Idiotypic vaccination: immunoprotection mediated by anti-idiotypic antibodies with antibiotic activity. Scand. J. Immunol. 37, 105–110 10.1111/j.1365-3083.1993.tb01671.x [DOI] [PubMed] [Google Scholar]
  58. Polonelli L., Lorenzini R., De Bernardis F., Morace G. (1986). Potential therapeutic effect of yeast killer toxin. Mycopathologia 96, 103–107 10.1007/BF00436668 [DOI] [PubMed] [Google Scholar]
  59. Polonelli L., Magliani W., Conti S., Bracci L., Lozzi L., Neri P., Adriani D., De Bernardis F., Cassone A. (2003). Therapeutic activity of an engineered synthetic killer antiidiotypic antibody fragment against experimental mucosal and systemic candidiasis. Infect. Immun. 71, 6205–6212 10.1128/IAI.71.11.6205-6212.2003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Polonelli L., Morace G. (1986). Reevaluation of the yeast killer phenomenon. J. Clin. Microbiol. 24, 866–869 [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Polonelli L., Morace G. (1987). Production and characterization of yeast killer toxin monoclonal antibodies. J. Clin. Microbiol. 25, 460–462 [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Polonelli L., Morace G. (1988). Yeast killer toxin-like anti-idiotypic antibodies. J. Clin. Microbiol. 26, 602–604 [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Polonelli L., Pontón J., Elguezabal N., Moragues M. D., Casoli C., Pilotti E., Ronzi P., Dobroff A. S., Rodrigues E. G., Juliano M. A., Maffei D. L., Magliani W., Conti S., Travassos L. R. (2008). Antibody complementarity-determining regions (CDRs) can display differential antimicrobial, antiviral and antitumor activities. PLoS ONE 3, e2371. 10.1371/journal.pone.0002371 [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Polonelli L., Séguy N., Conti S., Gerloni M., Bertolotti D., Cantelli C., Magliani W., Cailliez J. C. (1997). Monoclonal yeast killer toxin-like candidacidal anti-idiotypic antibodies. Clin. Diagn. Lab. Immunol. 4, 142–146 [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Rachini A., Pietrella D., Lupo P., Torosantucci A., Chiani P., Bromuro C., Proietti C., Bistoni F., Cassone A., Vecchiarelli A. (2007). An anti-beta-glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo. Infect. Immun. 75, 5085–5094 10.1128/IAI.00278-07 [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Samir P., Link A. J. (2011). Analyzing the cryptome: uncovering secret sequences. AAPS J. 13, 152–158 10.1208/s12248-011-9252-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Séguy N., Cailliez J. C., Delcourt P., Conti S., Camus D., Dei-Cas E., Polonelli L. (1997). Inhibitory effect of human natural yeast killer toxin-like candidacidal antibodies on Pneumocystis carinii. Mol. Med. 3, 544–552 [PMC free article] [PubMed] [Google Scholar]
  68. Séguy N., Polonelli L., Dei-Cas E., Cailliez J. C. (1998). Effect of a killer toxin of Pichia anomala to Pneumocystis. Perspectives in the control of pneumocystosis. FEMS Immunol. Med. Microbiol. 22, 145–149 10.1111/j.1574-695X.1998.tb01199.x [DOI] [PubMed] [Google Scholar]
  69. Selvakumar D., Miyamoto M., Furuichi Y., Komiyama T. (2006). Inhibition of fungal beta-1,3-glucan synthase and cell growth by HM-1 killer toxin single-chain anti-idiotypic antibodies. Antimicrob. Agents Chemother. 50, 3090–3097 10.1128/AAC.01435-05 [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Sobel J. D. (1997). Vaginitis. N. Engl. J. Med. 337, 1896–1903 10.1056/NEJM199712253372607 [DOI] [PubMed] [Google Scholar]
  71. Sonesson A., Kasetty G., Olin A. I., Malmsten M., Mörgelin M., Sørensen O. E., Schmidtchen A. (2011a). Thymic stromal lymphopoietin exerts antimicrobial activities. Exp. Dermatol. 20, 1004–1010 10.1111/j.1600-0625.2011.01391.x [DOI] [PubMed] [Google Scholar]
  72. Sonesson A., Nordahl E. A., Malmsten M., Schmidtchen A. (2011b). Antifungal activities of peptides derived from domain 5 of high-molecular-weight kininogen. Int. J. Pept. 2011, 761037. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Torosantucci A., Bromuro C., Chiani P., De Bernardis F., Berti F., Galli C., Norelli F., Bellucci C., Polonelli L., Costantino P., Rappuoli R., Cassone A. (2005). A novel glyco-conjugate vaccine against fungal pathogens. J. Exp. Med. 202, 597–606 10.1084/jem.20050749 [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Travassos L. R., Silva L. S., Rodrigues E. G., Conti S., Salati A., Magliani W., Polonelli L. (2004). Therapeutic activity of a killer peptide against experimental paracoccidioidomycosis. J. Antimicrob. Chemother. 54, 956–958 10.1093/jac/dkh430 [DOI] [PubMed] [Google Scholar]
  75. Ueki N., Someya K., Matsuo Y., Wakamatsu K., Mukai H. (2007). Cryptides: functional cryptic peptides hidden in protein structures. Biopolymers 88, 190–198 10.1002/bip.20687 [DOI] [PubMed] [Google Scholar]
  76. Vinh D. C. (2011). Insights into human antifungal immunity from primary immunodeficiencies. Lancet Infect. Dis. 11, 780–792 10.1016/S1473-3099(11)70217-1 [DOI] [PubMed] [Google Scholar]
  77. Wisplinghoff H., Bischoff T., Tallent S. M., Seifert H., Wenzel R. P., Edmond M. B. (2004). Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39, 309–317 10.1086/421946 [DOI] [PubMed] [Google Scholar]
  78. Zhai B., Lin X. (2011). Recent progress on antifungal drug development. Curr. Pharm. Biotechnol. 12, 1255–1262 10.2174/138920111796117292 [DOI] [PubMed] [Google Scholar]

Articles from Frontiers in Microbiology are provided here courtesy of Frontiers Media SA

RESOURCES